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Abstract
SET domain methyltransferases deposit methyl marks on specific histone tail lysine residues and play a major role in
epigenetic regulation of gene transcription. We solved the structures of the catalytic domains of GLP, G9a, Suv39H2 and
PRDM2, four of the eight known human H3K9 methyltransferases in their apo conformation or in complex with the methyl
donating cofactor, and peptide substrates. We analyzed the structural determinants for methylation state specificity, and
designed a G9a mutant able to tri-methylate H3K9. We show that the I-SET domain acts as a rigid docking platform, while
induced-fit of the Post-SET domain is necessary to achieve a catalytically competent conformation. We also propose a model
where long-range electrostatics bring enzyme and histone substrate together, while the presence of an arginine upstream
of the target lysine is critical for binding and specificity.
Enhanced version: This article can also be viewed as an enhanced version in which the text of the article is
integrated with interactive 3D representations and animated transitions. Please note that a web plugin is required
to access this enhanced functionality. Instructions for the installation and use of the web plugin are available in
Text S1.
Citation: Wu H, Min J, Lunin VV, Antoshenko T, Dombrovski L, et al. (2010) Structural Biology of Human H3K9 Methyltransferases. PLoS ONE 5(1): e8570.
doi:10.1371/journal.pone.0008570
Editor: Nick Gay, University of Cambridge, United Kingdom
Received September 30, 2009; Accepted November 15, 2009; Published January 11, 2010
Copyright:  2010 Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work is supported by the Structural Genomics Consortium (SGC), a registered charity (number 1097737) that receives funds from the Canadian
Institutes for Health Research, the Canadian Foundation for Innovation, Genome Canada through the Ontario Genomics Institute, GlaxoSmithKline, Karolinska
Institutet, the Knut and Alice Wallenberg Foundation, the Ontario Innovation Trust, the Ontario Ministry for Research and Innovation, Merck & Co., Inc., the
Novartis Research Foundation, the Swedish Agency for Innovation Systems, the Swedish Foundation for Strategic Research and the Wellcome Trust. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: matthieu.schapira@utoronto.ca (MS); alexander.plotnikov@mssm.edu (ANP)
¤ Current address: Department of Structural and Chemical Biology, Icahn Medical Institute, Mount Sinai School of Medicine, New York, New York, United States of
America
Introduction
Post-translational modifications of histone proteins regulate
chromatin compaction, mediate epigenetic regulation of tran-
scription, and control cellular differentiation in health and disease
[1,2]. Methylation of histone tails is one of the fundamental events
of epigenetic signaling [3]. Tri-methylation of lysine 9 of histone 3
(H3K9) mediates chromatin recruitment of HP1, heterochromatin
condensation and gene silencing [4,5]. Similarly, methylation of
H3K27 and H4K20 are associated with a repressed state of
chromatin, whereas expressed genes are methylated at H3K4,
H3K36 and H3K79 ([3,6] for review). Histone methyltransferases
are divided into protein arginine methyltransferases (PRMTs) and
histone lysine methyltransferases (HKMTs). HKMTs catalyze the
transfer of a methyl group from the co-factor S-adenosyl-L-
methionine (SAM) to a substrate lysine and, with the exception of
DOT1L, are all organized around a canonical SET domain [7,8].
The structures of a number of HKMTs have been reported,
including ternary complexes of human orthologs with co-factor
and substrate peptides (SETD7-H3K4, SETD8-H4K20 and
MLL1-H3K4 [9,10,11,12]), as well as N. crassa Dim-5 in complex
with a H3K9 peptide [13] and a viral protein complexed to
H3K27 [14] (Figure 1). These structures collectively highlighted a
remarkable plasticity of the peptide-binding site and a lack of clear
structural motifs that correlate with sequence selectivity [8,15].
Methylation of H3K9 in humans relies mostly on members of
the Suv39 family, namely EHMT1/GLP, EHMT2/G9a,
SUV39H1, SUV39H2, SETDB1 and SETDB2, as well as then
non-Suv39 enzymes PRDM2 and ASH1L [6] (Figure 1). Here we
report the high-resolution crystal structures of the methyltransfer-
ase domains of GLP, G9a, SUV39H2 and PRDM2, and propose
a structural mechanism for substrate recognition. Our data also
provide important insight to guide the development of potent
and selective inhibitors of HKMTs, which are likely to have
applications in a variety of diseases including regenerative
medicine, oncology and inflammation [16,17,18,19,20] ([21,22]
for review).
Results and Discussion
Overall Structure
We have solved the crystal structures of the catalytic domain of
four H3K9 methyltransferases: (1) the complexes of GLP/
EHMT1 co-crystallized with the co-factor product S-adenosyl-L-
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8570homocysteine (SAH) alone (accession code 2IGQ) and with an
H3K9me (accession code 3HNA) or H3K9me2 peptide (accession
code 2RFI), (2) G9a/EHMT2 (accession code 2O8J) and
SUV39H2 (accession code 2R3A) in complex with SAH and
SAM respectively, and (3) the non Suv39 protein PRDM2
(accession code 2QPW). The Suv39 structures G9a, GLP and
SUV39H2 adopt a typical fold composed of a conserved SET
domain and variable I-SET insert, flanked by Pre- and Post-SET
regions, and characterized by canonical features such as a pseudo-
knot next to the catalytic site, distinct co-factor and substrate
binding areas meeting at the site of methyl transfer, and a narrow
substrate lysine docking channel [8,23,24]. The four structures are
also characterized by the presence of an N-SET region located N-
terminal to the Pre-SET, that wraps around the core SET domain
(Figure 2A–D). The H3K9 peptide lies in a groove formed by the
I-SET and Post-SET domains (Figure 2A), as previously observed
Figure 1. Phylogenetic tree of human histone methyltransferases. Phylogeny is based on a multiple sequence alignment of the
methyltransferase domain including the N-SET, Pre_SET, SET, I-SET, and Post-SET motifs. Substrate selectivity was extracted from Kouzarides [1].
Enzymes with solved structure are highlighted by a frame, dotted if no peptide substrate complex is available. Structures solved in the present work
are framed in red.
doi:10.1371/journal.pone.0008570.g001
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with the enzyme through both backbone and side-chain inter-
actions (Figure 2E).
Methylation State Specificity
Mono-, di- or tri- methylation of H3K9 constitute distinct
biochemical signals and are established by distinct histone
methyltransferases; G9a and GLP are mono- and di-methylases,
and SUV39H2 di- and tri-methylates a mono-methylated
substrate. The specificity of PRDM2 is unknown [25]. Several
aromatic residues line the GLP channel occupied by the substrate
lysine leading to the catalytic site and contribute to methylation
state specificity as previously noted for several other HKMTs
[9,12,26,27]. Two residues are of particular importance for
catalysis. First, a conserved tyrosine residue of the post-SET
domain (Y1211 in GLP and Y1154 in G9a) is a major component
of the lysine binding channel while its hydroxyl group participates
in catalysis. This residue cannot be mutated without losing
catalytic activity (Figure 3) [8,28]. Second, the hydroxyl group of
GLP’s Y1124 (Y1067 in G9a) hydrogen-bonds to the methyl-
accepting nitrogen, thereby inhibiting an orientation of the
dimethyl-amine that would favor transfer of a methyl from
SAM, as was previously shown for SETD7 ([12,28] for review). To
confirm this model, we showed that, unlike wild-type G9a, the
Y1067F mutant is able to tri-methylate H3K9 (Figure 3).
Similarly, it was shown that the F1152Y G9a mutant can only
mono-methylate H3K9 [29]. Our structures show that this residue
is perfectly superimposed with GLP’s F1209 (0.1 A ˚ RMSD),
which, if mutated to Tyr, would hydrogen-bond with the e-amine
nitrogen of H3K9 and impair the alignment of the accepting
amine’s lone pair with the methyl-sulfur bond of SAM (Figure 3).
Thus, the methylation state selectivity appears to be inversely
proportional to the number of tyrosine residues surrounding the
methyl accepting nitrogen.
I-SET Is a Rigid Peptide-Docking Platform
The structure of the I-SET domain appears relatively
conserved, whether in the apo, co-factor-, or peptide-bound form,
Figure 2. Structures of four human H3K9 HKMTs. (A) a ternary complex of GLP with SAH and a H3K9Me substrate peptide, (B) G9a in complex
with SAH, (C) SUV39H2 in complex with SAM and (D) PRDM2, highlighting Pre-Set, SET, I-SET, Post-SET domains and the conserved presence of an N-
SET domain. The co-factor is shown as yellow sticks. Residues flanking un-resolved regions are connected by dotted lines. (E) The detail of the
interactions between GLP and an H3K9Me peptide.
doi:10.1371/journal.pone.0008570.g002
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b-sheet, linked by loops of variable lengths (Figure 4). Superim-
position of our six new H3K9 methyltransferase structures (see
Materials and Methods) shows that in all cases the first b-strand is
in a conformation which would preserve the pair of backbone
hydrogen-bonds observed between Lys-9 substrate and strand-1 of
I-SET in the GLP-peptide complex (Figure 4). Furthermore, a
systematic comparison of the ternary structures presented here for
GLP-H3K9 and previously published for Dim-5-H3K9, SETD8-
H4K20, SETD7-H3K4, SETD7-TAF10, SETD7-P53, vSET-
H3K27 reveals that this pair of hydrogen bonds between the
backbone of a single substrate peptide residue and the first strand
of I-SET is observed (1) in all HKMT ternary structures to date
and (2) always and only at the substrate lysine (Figure 5A–E -
SETD7-TAF10 and SETD7-P53 complexes not shown). This
suggests that an evolutionary pressure enforces conservation of this
‘‘double hydrogen-bond’’, which likely plays an important role in
the binding mechanism, probably by imposing the proper
orientation of the peptide when lysine inserts into the active site;
flipping the substrate by 180u in its groove would not allow
formation of the double hydrogen bond.
Our structures single-out residue R-1 of H3 (the methylated
lysine is used as reference position 0 for peptide residue numbering
throughout the text) as the major contributor to the interaction
after the substrate lysine itself, with four direct hydrogen-bonds
between the arginine guanidinium group and GLP (Figure 2E).
This is in agreement with recent mutational analysis showing that
no substitution at position -1 is tolerated by G9a [30]. This critical
interaction takes place exclusively with I-SET residues (Figure 5F).
GLP residues that contribute to substrate binding are conserved in
G9a (Figure S1), and it is reasonable to assume that the peptide
binding mode observed in GLP holds for G9a. On the other hand,
mutation of R-1 to alanine only mildly affects peptide binding to
Dim-5, a H3K9 methyltransferase in N. crassa [31], indicating that
the selectivity mechanism observed for human GLP and G9a is
not universal.
Intriguingly, our structures of GLP in complex with mono- or
di-methylated susbtrate peptides reveal that residue H3K4 is
making 2 hydrogen-bonds with the D1131 and D1145 side-chains
of the I-SET domain (Figure 6), which suggests that H3K4
methylation may lower binding affinity, and reduce H3K9
methylation efficiency. We tested this hypothesis, and observed a
Figure 3. Structural determinants of G9a mono/di-methylation specificity. A model of substrate lysine-bound G9a (Top panel) was
generated from the superposition of the active sites of the GPL ternary complex and GLP. Y1067 of G9a stabilizes the di-methylamine end of the
substrate lysine in an orientation where the lone-pair is not facing the co-factor, thereby disfavoring transfer of a third methyl group. The Y1067F
mutant loses this restriction and can tri-methylate its substrate, as indicated in the table. Previous work had shown that the F1152Y G9a mutant can
only mono-methylate H3K9 [29].
doi:10.1371/journal.pone.0008570.g003
Structure of H3K9 HMTs
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trimethylated at lysine 4, and similar reduction in enzymatic
efficiency, while Kcat was unaffected. Mono and di-methylation of
H3K4 had no or very limited effect (data not shown). It is not clear
whether this variation is biologically significant.
These results suggest a model in which a mostly pre-formed I-
SET domain acts as a receiving platform for the histone 3 tail.
Binding includes a conserved pair of hydrogen-bonds with the
backbone of the substrate lysine, and critical contacts with a basic
side-chain upstream of the methyl acceptor.
Mobile Post-SET Domain Closes onto the Peptide
Substrate
The Post-SET domains of G9a, GLP, SUV39H2, but not
PRDM2 include a ZnCys motif previously observed in the
structures of Dim-5 [13] and the H3K4 methyltransferase MLL1
[10]. The Post-SET domains of G9a and GLP present an a-helix
that contributes to peptide binding where other HKMTs have a
loop. Unlike I-SET, Post-SET is absent from the PRDM2
structure, which lacks co-crystallized SAM or SAH (Figure 2D).
It is partially folded in the structures of G9a and SUV39H2 in
complex with SAH and SAM respectively (Figure 2B–C), and fully
ordered in the ternary complexes of GLP with SAH and H3K9
peptide (Figure 2A). As previously observed with other HKMTs
([9,11,8] for review), the co-factor contributes to the formation of a
hydrophobic, mostly aromatic cluster (composed of Post-SET
Y1211/Y1154/Y261, F1215/F1158, W1216/W1159/L298,
F1223/F1166/T285 and SET H1170/H1113/H220 in GLP/
G9a/SUV39H2) necessary for partial folding of the Post-SET
domain. Surprisingly, in our structure of SUV39H2, Post-SET
Lys-264 is inserted into the partially formed substrate lysine
binding channel, which may represent some form of auto-
inhibitory mechanism (Figure 7). Post-SET is fully structured only
when bound to the substrate peptide (Figure 2A), or to a small
molecule inhibitor [32], but the density is incomplete otherwise
(Figure 2B–D). This implies that Post-SET is naturally flexible,
which may be important for peptide turn-over, as recently
proposed [10].
Altogether, these results suggest the presence of three confor-
mational states for the Post-SET domain. (1) A flexible or even
disordered state when no co-factor or peptide is bound. (2) A loose
conformation when SAM or SAH, but no peptide is bound, which
may also accommodate non-specific sequences. (3) A more rigid
conformation in which the I-SET domain closes onto the substrate
peptide. These states are probably in a dynamic equilibrium, with
the co-factor and substrate shifting the equilibrium toward
conformation 3.
Long Range Electrostatics Attract Histone Peptides to the
HKMT Binding Groove
Histone tails are rich in lysines and arginines and consequently
are electropositive (Figure 8A). Mapping the electrostatic potential
along the molecular surface of GLP, G9a, SUV39H2 and
PRDM2 shows that the peptide-binding groove is consistently
electronegative (Figure 8B–E). This feature is also conserved in the
structure of the N. crassa H3K9 methyltransferase Dim-5
(Figure 8F). This suggests that non-specific long-range electrostatic
attractions play an evolutionarily conserved role in guiding the
substrate-binding groove towards histone tails.
Based on the four HKMT structures presented here, we
propose a mechanism for selective lysine H3K9 methylation, in
which (1) long-range electrostatics attract the enzyme onto basic
histone tails, (2) a pre-formed I-SET domain carries structural
determinants necessary for specific interactions with the substrate
peptide, and (3) catalytically competent conformation is achieved
by subsequent closing of the Post-SET domain on the substrate.
Considering the electronegative potential of the binding groove,
our analysis suggests that HKMT inhibitors should be rather
basic. To achieve selectivity, inhibitors should bind sites with clear
interaction field potential occupied by residues distal to the
substrate lysine. A recent co-crystal structure of the first specific
HKMT inhibitor supports these general concepts [32].
Materials and Methods
Cloning, Expression and Purification of Human GLP
DNA fragments encoding the methyltransferase domain of
human GLP (residues 951-1235), G9a (residues 913–1193),
SUV39H2 (residues 112–410) and PRDM2 (residues 2–148) were
amplified by PCR and sub-cloned into the pET28a-LIC vector
(http://www.sgc.utoronto.ca/SGC-WebPages/toronto-vectors.php),
downstream of the poly-histidine coding region. The methyl-
transferase domains of the above proteins were expressed in E.coli
BL21 (DE3) codon plus RIL strain (Stratagene) by addition of
1 mM isopropyl-1-thio-D-galactopyranoside and incubated over-
night at 15uC. The proteins were purified as following: harvested
cells were resuspended in phosphate-buffered-saline (pH 7.4)
supplemented with 250 mM NaCl, 2 mM b-mercaptoethanol,
5% glycerol, 0.1% Igepal and 1 mM phenylmethyl sulfonyl
fluoride. The cells were lysed by passing through a microfluidizer
(Microfluidics Corp.). The lysate was loaded onto a 5 ml HiTrap
Chelating column (GE Health Care), charged with Ni
2+. The
column was washed with 10 column volume of 20 mM Tris-HCl
(pH 8.0), containing 250 mM NaCl and 50 mM imidazole, 5%
Figure 4. The I-SET domain is relatively rigid and structurally
conserved. Structural superimposition of the ternary GLP structure with
G9a or Suv39H2 in complex with co-factor and with the apo-structure of
PRDM2 shows that the I-SET (cyan) conformation is conserved. The
backboneatoms engaged in a doublehydrogen-bondwith the substrate
lysine observed in all available HKMT-peptide complexes are already
positioned in the absence of peptide or co-factor.
doi:10.1371/journal.pone.0008570.g004
Structure of H3K9 HMTs
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Tris-HCl, pH 8.0, 250 mM NaCl, 250 mM imidazole, 5%
glycerol). The protein was loaded onto a Superdex 200 column
(GE Health Care) equilibrated with 20 mM Tris-HCl (pH 8.0)
and 150 mM NaCl. Thrombin (Sigma) was added to combined
fractions containing the target proteins to remove the His6- tag.
The protein was further purified to homogeneity by ion-exchange
chromatography.
Crystallization
Purified GLP, G9a and SUV39H2 proteins were crystallized in
the presence of S-adenosyl-L-homocysteine (Sigma) or S-adenosyl-
L-methionine (Sigma) using the hanging drop vapor diffusion
method at 20uC by mixing equal volume of the protein solution
with the reservoir solution. The GLP-SAH binary complex
(protein/SAH molar ratio of 1:5) was crystallized in 20% PEG
4,000, 10% isopropanol, 0.1 M HEPES (pH 7.5). The G9a-SAH
complex (protein/SAH molar ratio of 1:5) was crystallized in 20%
PEG 3,350, 0.2 M NaF, 0.1 M Bis-Tris propane (pH 7.5), 5%
ethyleneglycol.TheSUV39H2-SAMcomplex(protein/SAMmolar
Figure 5. Backbone and side-chain contributions to peptide binding. A–E: Both Post-SET (blue) and I-SET (cyan) backbone atoms are
engaged in a network of hydrogen-bonds with the peptide main-chain (magenta). A pair of hydrogen-bonds between backbone atoms of the I-SET
and substrate lysine are conserved in all available HKMTs ternary complexes to date (dotted lines flanking red arrow). F: the substrate peptide sits ina
groove formed by the I-SET (cyan) and the Post-SET (blue) domains. Peptide side-chains contributing most to the interaction are shown (magenta
sticks). The guanidinium group of H3R8 (R-1) makes extensive contacts with the I-SET domain.
doi:10.1371/journal.pone.0008570.g005
Figure 6. Contribution of H3K4 to H3K9 binding. Our structures
of GLP in complex with H3K9me or H3K9me2 show that H3K4 folds on
top of H3R8, making polar interactions with D1131 and D1145 of GLP.
doi:10.1371/journal.pone.0008570.g006
Structure of H3K9 HMTs
PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8570ratio of 1:10) was crystallized in 20% PEG 10, 000, 0.1 M HEPES
(pH 7.5). The GLP-SAH-H3K9me and GLP-SAH-H3K9me2
complexes (protein/SAH/peptide molar ratio of 1:5:10) were
crystallized in 16% PEG 4,000, 10% isopropanol, 0.1 M HEPES
(pH 7.5). Purified PRDM2 was crystallized using hanging drop
vapor diffusion method at 20uCb ym i x i n g1 . 5ml of the protein
solution with 1.5 ml of the reservoir solution containing 22% PEG
5,000 MME, 0.2 M ammonium sulfate, 0.1 M MES (pH 7.0). All
the crystals were soaked in the corresponding mother liquor
supplemented with 20% glycerol as cryoprotectant before freezing
in liquid nitrogen, except the G9a-SAH complex crystals, for which
paraton-N was used as cryoprotectant.
Data Collection and Structure Determination
X-ray diffraction data were collected at 100 K at beamline
17ID of Advanced Photon Source (APS) at Argonne National
Laboratory, beamline X25 of the National Synchrotron Light
Source, beamline A1 of Cornell High Energy Synchrotron Source
(CHESS), Cornell University, and a Rigaku FR-E home source.
Data were processed using the HKL-2000 software suite [33]. The
structuresofmethyltransferasedomainofGLP,G9a,andSUV39H2
weresolved bymolecular replacement using theprogram MOLREP
[34]. ARP/wARP [35] was used for automatic model building.
Graphics program COOT [36] was used for model building and
Figure 7. Auto-inhibitory conformation of SUV39H2. In our
structure of SUV39H2, the C-terminus of the Post-Set domain (blue) adopts
a conformation that positions its K264 side-chain (blue sticks) half-way into
the substrate lysine channel (gray mesh). The H3K9me peptide (magenta)
from a superimposed GLP-H3K9me structure is shown as a reference. SET
and Post-SET of SUV39H2 are colored green and blue respectively.
doi:10.1371/journal.pone.0008570.g007
Figure 8. Electrostatic component to H3K9 peptide binding. While the overall electrostatic profile of available H3K9 methyltransferases
structures varies, the peptide-binding groove is consistently electronegative (B–E: this work, F: N. crassa methyltransferase Dim-5), in contrast with the
largely positive electrostatic potential of histone tails (A). When present, the substrate peptide is shown in magenta. Residues 264–267 of SUV39H2
were partially occupying the binding site and were removed. The Post-SET domain of PRDM2 is entirely disordered and the position of the substrate
lysine binding channel is indicated with a black arrow.
doi:10.1371/journal.pone.0008570.g008
Structure of H3K9 HMTs
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PLoS ONE | www.plosone.org 8 January 2010 | Volume 5 | Issue 1 | e8570visualization. PRDM2 structure was solved by single-wavelength
anomalous diffraction (SAD) at low resolution, using a seleno-
methionine derivative crystal with the program SHELXD [37], and
the phasing was performed using SHELXE [38]. The low resolution
structure was used as model to solve the native structure at higher
resolution. Crystal diffraction data and refinement statistics for the
structure are displayed in Table 1. One residue is in a disallowed
area of the Ramachandran plot in our GLP (M1049) and G9a (I992)
structures. This strained residue maps at a conserved location,
remote from the peptide and cofactor binding sites.
Histone Methyltransferase Assay
The SAHH-coupled assay described by Collazo et al. [39] was
optimized and employed to assay the activity of G9a. This assay
utilizes S-adenosylhomocysteine hydrolase (SAHH) to hydrolyze
the methyltransfer product S-adenosylhomocysteine to homocys-
teine and adenosine in the presence of adenosine deaminase which
converts adenosine to inosine. The homocysteine concentration is
then determined through conjugation of its free sulfhydryl moiety
to a thiol-sensitive fluorophore, ThioGlo (Calbiochem). Assays
were performed at room temperature in 25 mM potassium
phosphate buffer pH 8, 1 mM EDTA, 2 mM MgCl2 and 0.01%
Tween 20. Series of control experiments were conducted to
establish the optimum assay condition for each methyltransferase
and the optimum conditions were used to determine the kinetic
parameters for GLP. Assay cocktails were prepared with 5 mM
SAHH to avoid any SAH accumulation while produced from the
methyltransferase reaction, 3 U/ml of adenosine deaminase from
Sigma, 70 mM SAM, and GLP. The peptide concentrations were
varied over the range of 2 mM to 4 mM. Assays were initiated by
the addition of peptide and immediately after starting the reaction,
2x volume of 20 mM ThioGlo solution was added to each well.
The methylation reaction was followed by monitoring the increase
in fluorescence using Biotek Synergy2 plate reader with 360/
40 nm excitation filter and 528/20 nm emission filter for 20 min
in 384 well-plate format. Homocysteine generated in the assay was
quantified using standard curves. Activity values were corrected by
subtracting background caused by the peptide or the protein. Km
and kcat values were calculated using the Michaelis-Menten
equation and Sigmaplot 9.0. Standard deviations were calculated
from two independent experiments.
Structure Superimposition and Electrostatic Potential
Coloring
Optimal structure superimpositions were identified with ICM
(Molsoft LLC). Briefly, the algorithm uses an iterative procedure to
find the best ‘‘alignable’’ main chain core in both structures based
on seed alignments of 15 residues as follows: (1) start with the most
reliable seed alignment of 15 residues; (2) set all weights to 1; (3)
perform weighted superposition and evaluate RMSD; (4) calculate
the deviation Di for each backbone atom pair; (5) sort the deviations
and find the deviation D50 corresponding to 50-percentile of the
deviation array; (6) calculate weights W according to the formula
Wi=exp(-D50
2/Di
2); (7) go back to step 3 unless a limit of 10
iterations is reached. The electrostatic potential was calculated with
ICM using a boundary element solution of the Poisson equation.
Color saturation was set to calculated values of +/2 5 kcal/electron
units (+5=blue 25=red) when the electrostatic potential was
projected on molecular surfaces.
Supporting Information
Figure S1 Sequence alignment of the methyltransferase domain
of H3K9 HKMTs. Residues within 4A ˚ of bound H3K9 peptide in
our GLP-H3K9me complex are highlighted in red. The three
aspartate making polar interactions with arginine H3R8 are
colored blue. The sequence of PRDM2 is too divergent from other
H3K9 HKMTs and was not included in the alignment. Large
inserts present in SETDB1 and SETDB2 sequences are not shown
for clarity.
Found at: doi:10.1371/journal.pone.0008570.s001 (1.11 MB TIF)
Datapack S1 Standalone iSee datapack - contains the enhanced
version of this article for use offline. This file can be opened using
free software available for download at http://www.molsoft.com/
icm_browser.html.
Found at: doi:10.1371/journal.pone.0008570.s002 (ICB)
Text S1 Instructions for installation and use of the required web
plugin (to access the online enhanced version of this article).
Found at: doi:10.1371/journal.pone.0008570.s003 (0.75 MB
PDF)
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